Swedish Orphan Biovitrum AB (publ) (LON:0MTD)
322.81
+4.81 (1.51%)
At close: Dec 17, 2025
LON:0MTD Revenue
Swedish Orphan Biovitrum AB had revenue of 7.78B SEK in the quarter ending September 30, 2025, with 12.79% growth. This brings the company's revenue in the last twelve months to 27.85B, up 9.50% year-over-year. In the year 2024, Swedish Orphan Biovitrum AB had annual revenue of 26.03B with 17.65% growth.
Revenue (ttm)
27.85B SEK
Revenue Growth
+9.50%
P/S Ratio
4.09
Revenue / Employee
15.42M SEK
Employees
1,806
Market Cap
8.99B GBP
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.03B | 3.90B | 17.65% |
| Dec 31, 2023 | 22.12B | 3.33B | 17.74% |
| Dec 31, 2022 | 18.79B | 3.26B | 21.00% |
| Dec 31, 2021 | 15.53B | 268.00M | 1.76% |
| Dec 31, 2020 | 15.26B | 1.01B | 7.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 138.32B |
| Unilever | 51.24B |
| AstraZeneca | 43.24B |
| HSBC Holdings | 43.13B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| Barclays | 26.02B |